Granules India Limited (GRANULES.BO)
INR 600.35
(0.58%)
INR 600.35
(0.58%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 16.79 Billion INR | -20.49% |
| 2022 | 21.12 Billion INR | 19.49% |
| 2021 | 17.68 Billion INR | 1.56% |
| 2020 | 17.41 Billion INR | 41.58% |
| 2019 | 12.29 Billion INR | 29.57% |
| 2018 | 9.49 Billion INR | 33.8% |
| 2017 | 7.09 Billion INR | 0.31% |
| 2016 | 7.07 Billion INR | 16.1% |
| 2015 | 6.09 Billion INR | 33.2% |
| 2014 | 4.57 Billion INR | 19.2% |
| 2013 | 3.83 Billion INR | 59.88% |
| 2012 | 2.39 Billion INR | 2.59% |
| 2011 | 2.33 Billion INR | 172.94% |
| 2010 | 856.83 Million INR | -4.46% |
| 2009 | 896.81 Million INR | 0.0% |
| 2008 | - INR | -100.0% |
| 2007 | 520.14 Million INR | 29.87% |
| 2006 | 400.5 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 4.78 Billion INR | -4.46% |
| 2023 Q4 | 5.01 Billion INR | -23.84% |
| 2023 Q3 | 6.58 Billion INR | 7.14% |
| 2023 FY | 16.79 Billion INR | -20.49% |
| 2023 Q1 | 5.06 Billion INR | 5.4% |
| 2023 Q2 | 6.14 Billion INR | 21.34% |
| 2022 Q4 | 4.8 Billion INR | -13.35% |
| 2022 Q3 | 5.54 Billion INR | -3.12% |
| 2022 FY | 21.12 Billion INR | 19.49% |
| 2022 Q1 | 5.06 Billion INR | 29.44% |
| 2022 Q2 | 5.72 Billion INR | 13.09% |
| 2021 Q4 | 3.9 Billion INR | -15.91% |
| 2021 Q1 | 4.6 Billion INR | 30.71% |
| 2021 FY | 17.68 Billion INR | 1.56% |
| 2021 Q3 | 4.64 Billion INR | 2.9% |
| 2021 Q2 | 4.51 Billion INR | -1.96% |
| 2020 Q1 | 4.38 Billion INR | 88.14% |
| 2020 Q2 | 4.97 Billion INR | 13.47% |
| 2020 Q4 | 3.52 Billion INR | -22.27% |
| 2020 FY | 17.41 Billion INR | 41.58% |
| 2020 Q3 | 4.53 Billion INR | -8.75% |
| 2019 Q4 | 2.32 Billion INR | -34.77% |
| 2019 Q1 | 2.99 Billion INR | 44.71% |
| 2019 Q3 | 3.56 Billion INR | 4.93% |
| 2019 Q2 | 3.4 Billion INR | 13.45% |
| 2019 FY | 12.29 Billion INR | 29.57% |
| 2018 Q3 | 2.72 Billion INR | 3.6% |
| 2018 FY | 9.49 Billion INR | 33.8% |
| 2018 Q1 | 2.06 Billion INR | 6.19% |
| 2018 Q2 | 2.63 Billion INR | 27.68% |
| 2018 Q4 | 2.07 Billion INR | -24.0% |
| 2017 Q1 | 1.97 Billion INR | -0.77% |
| 2017 FY | 7.09 Billion INR | 0.31% |
| 2017 Q4 | 1.94 Billion INR | -3.82% |
| 2017 Q3 | 2.01 Billion INR | 3.56% |
| 2017 Q2 | 1.94 Billion INR | -1.35% |
| 2016 FY | 7.07 Billion INR | 16.1% |
| 2016 Q4 | 1.99 Billion INR | 6.83% |
| 2016 Q3 | 1.86 Billion INR | 5.65% |
| 2016 Q2 | 1.76 Billion INR | 4.3% |
| 2016 Q1 | 1.69 Billion INR | -4.91% |
| 2015 FY | 6.09 Billion INR | 33.2% |
| 2015 Q4 | 1.77 Billion INR | 33.43% |
| 2015 Q2 | 1.33 Billion INR | 4.73% |
| 2015 Q1 | 1.27 Billion INR | 13.09% |
| 2015 Q3 | 1.33 Billion INR | -0.27% |
| 2014 Q4 | 1.12 Billion INR | -5.03% |
| 2014 Q3 | 1.18 Billion INR | 3.28% |
| 2014 Q2 | 1.15 Billion INR | 4.05% |
| 2014 FY | 4.57 Billion INR | 19.2% |
| 2014 Q1 | 1.1 Billion INR | 2.68% |
| 2013 Q3 | 1.04 Billion INR | 11.39% |
| 2013 Q4 | 1.07 Billion INR | 2.55% |
| 2013 Q2 | 942.57 Million INR | 22.93% |
| 2013 Q1 | 766.78 Million INR | -49.93% |
| 2013 FY | 3.83 Billion INR | 59.88% |
| 2012 Q3 | 561.44 Million INR | -3.05% |
| 2012 Q4 | 1.53 Billion INR | 172.75% |
| 2012 FY | 2.39 Billion INR | 2.59% |
| 2012 Q1 | 534.59 Million INR | 0.0% |
| 2012 Q2 | 579.12 Million INR | 8.33% |
| 2011 FY | 2.33 Billion INR | 172.94% |
| 2010 FY | 856.83 Million INR | -4.46% |
| 2009 FY | 896.81 Million INR | 0.0% |
| 2008 FY | - INR | -100.0% |
| 2007 FY | 520.14 Million INR | 29.87% |
| 2006 FY | 400.5 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 20.246% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -979.276% |
| Sigachi Industries Limited | 2 Billion INR | -739.006% |
| Bal Pharma Limited | 770.19 Million INR | -2081.172% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | -171.203% |
| Medico Remedies Limited | 262.14 Million INR | -6308.417% |
| Lasa Supergenerics Limited | 121.02 Million INR | -13780.261% |
| Venus Remedies Limited | 2.18 Billion INR | -669.696% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 2888.697% |
| Alpa Laboratories Limited | 188.89 Million INR | -8793.449% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -465.24% |
| Shilpa Medicare Limited | 3.54 Billion INR | -373.638% |
| Aarti Drugs Limited | 8.31 Billion INR | -102.007% |
| Lupin Limited | 123.71 Billion INR | 86.421% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 89.14% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 86.583% |
| Windlas Biotech Limited | 1.33 Billion INR | -1154.801% |
| Suven Life Sciences Limited | -200.79 Million INR | 8466.3% |
| Eris Lifesciences Limited | 10.42 Billion INR | -61.117% |
| Valiant Laboratories Limited | -60.66 Million INR | 27792.338% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 25.994% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -1850.683% |
| Ipca Laboratories Limited | 29.8 Billion INR | 43.645% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -354.595% |
| Achyut Healthcare Limited | 4.86 Million INR | -345493.088% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 93.501% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -1041.406% |
| RPG Life Sciences Limited | 2.48 Billion INR | -576.572% |
| Mankind Pharma Limited | 44.52 Billion INR | 62.267% |
| Laurus Labs Limited | 24.62 Billion INR | 31.766% |
| Piramal Pharma Limited | 24.47 Billion INR | 31.35% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -1682.608% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 64.071% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 37.271% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 75.773% |
| Unichem Laboratories Limited | 4.86 Billion INR | -245.314% |
| Sequent Scientific Limited | 2.97 Billion INR | -463.975% |
| Novartis India Limited | 1.32 Billion INR | -1166.055% |
| Wanbury Limited | 1.73 Billion INR | -870.696% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -307.426% |
| Wockhardt Limited | 16.24 Billion INR | -3.444% |
| Themis Medicare Limited | 1.5 Billion INR | -1017.045% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -2474.247% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 14.477% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | -35.119% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 89.732% |
| Divi's Laboratories Limited | 32.44 Billion INR | 48.214% |
| NATCO Pharma Limited | 25.73 Billion INR | 34.725% |
| Gufic Biosciences Limited | 4.16 Billion INR | -303.082% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -266.732% |
| Ind-Swift Limited | 2.17 Billion INR | -673.258% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -190.575% |
| FDC Limited | 8.33 Billion INR | -101.557% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -8616.62% |
| Medicamen Biotech Limited | 495.49 Million INR | -3290.404% |
| Alkem Laboratories Limited | 52.29 Billion INR | 67.877% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -169.968% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -115123.77% |
| Brooks Laboratories Limited | 65.62 Million INR | -25500.853% |
| Megasoft Limited | 342.07 Million INR | -4811.051% |
| ZIM Laboratories Limited | 1.26 Billion INR | -1226.028% |
| Strides Pharma Science Limited | 14.38 Billion INR | -16.758% |
| Neuland Laboratories Limited | 8.24 Billion INR | -103.681% |
| Morepen Laboratories Limited | 6.16 Billion INR | -172.659% |
| Hikal Limited | 3.14 Billion INR | -434.485% |
| Indoco Remedies Limited | 6.04 Billion INR | -178.073% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -188.086% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -2607.478% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -2287.601% |
| Hester Biosciences Limited | 1.27 Billion INR | -1218.987% |